复星医药：控股子公司酮洛芬贴剂获准开展临床试验

Group 1 - The core point of the article is that Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received acceptance from the National Medical Products Administration for a drug registration application for a new indication of Sulfentanil injection, which is aimed at PD-L1 positive, resectable gastric cancer patients [1] - The application has been included in the priority review process by the regulatory authority [1] - Additionally, another subsidiary, Chaohui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for Ketorolac patch, which is intended for pain relief and anti-inflammatory purposes [1]